While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
The new Omicron SARS-CoV2 variant first identified in South Africa but now appearing in Asia and Europe is causing alarm worldwide as its multiple mutations could make it more transmissible than the Delta variant, and potentially able to evade existing vaccines.
News of the variant, also known as B.1.1
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
